Glra1 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
| GLRA1 — Glycine Receptor Alpha-1 Subunit | |
|---|---|
| Full Name | Glycine Receptor Alpha-1 Subunit |
| Gene Symbol | GLRA1 |
| UniProt ID | P23415 |
| NCBI Gene | 2741 |
| Chromosome | 5q33.1 |
| Protein Length | 456 amino acids |
| Molecular Weight | ~52 kDa |
| Protein Family | Cys-loop receptor family, Ligand-gated chloride channel |
| Subcellular Localization | Plasma membrane, Postsynaptic membranes |
| Brain Expression | Spinal cord, Brainstem, Cerebellum, Hippocampus |
| Diseases | Hyperekplexia, Neurological Disorders |
The GLRA1 protein (Glycine Receptor Alpha-1 Subunit) is a critical component of inhibitory neurotransmission in the central nervous system. It encodes the α1 subunit of the glycine receptor (GlyR), a ligand-gated chloride channel that mediates fast inhibitory synaptic transmission primarily in the spinal cord and brainstem[1]. Glycine receptors are members of the Cys-loop receptor family, which also includes GABA_A receptors and nicotinic acetylcholine receptors. The α1 subunit is the most widely expressed isoform in adult mammals and is essential for motor control, sensory processing, and respiratory regulation[2].
Mutations in the GLRA1 gene cause hyperekplexia (also known as startle disease or stiff baby syndrome), a rare neurological disorder characterized by exaggerated startle responses and neonatal apnea. Understanding GLRA1 structure and function has provided crucial insights into inhibitory neurotransmission and has informed therapeutic development for disorders of motor control and neuromuscular hyperexcitability[3].
The GLRA1 protein consists of 456 amino acids and contains several distinct structural domains:
N-terminal Extracellular Domain (ECD): The first ~220 amino acids form the ligand-binding domain, which contains the characteristic Cys-loop motif (a 13-amino acid disulfide-bonded loop) shared by all Cys-loop receptors. This domain contains the binding sites for glycine and competitive antagonists[4].
Transmembrane Domains (TMD): Four hydrophobic transmembrane helices (TM1-TM4) span the plasma membrane. TM2 forms the channel pore, while TM4 contributes to receptor assembly and trafficking. The intracellular loop between TM3 and TM4 contains sites for phosphorylation and protein interactions[5].
C-terminal Intracellular Domain: The short intracellular loop between TM3 and TM4 contains phosphorylation sites (particularly serine/threonine residues) that modulate receptor trafficking and function.
The glycine receptor assembles as a pentamer, typically as a heteromeric assembly of α1 and β subunits. The α1 subunit can form homomeric channels in expression systems, which retain functional properties similar to native receptors. Each subunit contributes to the central pore, with the TM2 helices lining the ion conduction pathway[6].
Key structural features include:
GLRA1-containing glycine receptors mediate fast inhibitory neurotransmission in the spinal cord and brainstem. When glycine binds to the extracellular domain, it triggers a conformational change that opens the channel pore, allowing chloride ions to flow into the neuron. This hyperpolarizes the postsynaptic membrane, making it less likely to generate action potentials[7].
The receptor exhibits several key properties:
GLRA1 is highly expressed in:
The β subunit (GLRB) co-assembles with α1 to form heteromeric receptors with distinct pharmacological and kinetic properties. The β subunit anchors the receptor to the cytoskeleton via gephyrin, clustering receptors at postsynaptic sites[8].
RoleGlycine receptor-mediated inhibition is essential for:
Glycine binding induces a series of conformational changes:
The channel conducts Cl- ions with high selectivity. The narrowest part of the pore (~6 Å diameter) determines ion selectivity. Mutations affecting pore-lining residues can alter conductance and ion selectivity[9].
Hyperekplexia is caused by dominant or recessive mutations in GLRA1. The disorder is characterized by:
Over 50 pathogenic mutations have been identified in GLRA1:
Common mutations include:
GLRA1 mutations cause hyperekplexia through several mechanisms:
GLRA1 knockout mice exhibit:
GLRA1 interacts with several proteins:
Glra1 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Glra1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Betz H, et al. (1999). Structure and functions of inhibitory glycine receptors. Q Rev Biophys. 32(2):131-164. DOI:10.1017/S0033583500003538 ↩︎
Lynch JW (2004). Molecular structure and function of the glycine receptor chloride channel. Physiol Rev. 84(4):1051-1095. DOI:10.1152/physrev.00042.2003 ↩︎
Thomas RH, et al. (2013). Hyperekplexia: coloured early. Lancet Neurol. 12(3):293-294. DOI:10.1016/S1474-4422(1270294-6 ↩︎
Grudzinska J, et al. (2005). The glycine receptor beta subunit determines the glycine receptor stoichiometry. Neuron. 45(5):727-739. DOI:10.1016/j.neuron.2005.01.016 ↩︎
Burgos CF, et al. (2016). Molecular basis of ligand modulation of the glycine receptor. J Biol Chem. 291(7):3727-3738. DOI:10.1074/jbc.M115.694273 ↩︎
Miller PS, et al. (2008). Crystal structure of a bacterial Cys-loop receptor homolog. Nature. 454(7203):391-395. DOI:10.1038/nature07108 ↩︎
Betz H, et al. (2001). Glycine receptors: recent insights into their structural organization and signal transduction. Cell Tissue Res. 305(2):177-186. DOI:10.1007/s004410100367 ↩︎
Fritschy JM, et al. (2008). Gephyrin: a key protein in the organization of GABAergic and glycinergic postsynaptic membranes. Neuroscientist. 14(5):445-457. DOI:10.1177/1073858408316058 ↩︎
Moorhouse AJ, et al. (2002). Structure of the glycine receptor and its location in the central nervous system. Ann Neurol. 52(6):S16-S23. DOI:10.1002/ana.10481 ↩︎